Sign in
Not yet recruitingNo phase

Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation

Key facts

Who runs it
Moscow Multidisciplinary Clinical Center "Kommunarka"
Where
Russia7 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
76 people, planned
Started
25 Jun 2026
Expected to end
25 Dec 2027
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Efferon LPS
  • Toramyxin PMX 20R
  • Jafron HA 330
  • CytoSorb
Record updated
2 July 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (19)Hide the full registry criteria

Who can take part

  • Septic shock according to SEPSIS-3 criteria
  • Age: 18-80 years
  • SOFA ≥9 points
  • Diagnosis of septic shock established <12 hours ago
  • Invasive hemodynamic monitoring
  • Norepinephrine dose >0.2 mcg/kg/min

Who cannot take part

  • End-stage heart failure (NYHA stage IV)
  • Ongoing bleeding
  • HIV infection
  • Patients with oncohematological diseases
  • Patients with a recognized palliative status or the definition of "metastatic cancer"
  • Absolute neutrophil count less than 500 cells/μL
  • Pregnancy
  • Pulmonary embolism with obstructive shock
  • Atonic coma
  • More than 30 points on the MELD scale, class C on the Child-Pugh scale
  • Burns over 10% of the body surface area
  • RRT using membranes with a high cutoff point and increased adsorption capacity within 72 hours from the initiation of the first hemoadsorption procedure
  • Use of plasma exchange within 72 hours from the initiation of the first hemoadsorption procedure

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Septic shock

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation. A Pilot Multicenter Randomized Controlled Trial.

Read full original descriptionShow less

The goal of this clinical trial is the estimation of the efficacy and safety of hemoadsorption procedures (LPS (Lipopolysaccharide) and inflammatory mediators adsorption) in participants with septic shock.

The main questions it aims to answer are:

Does hemoadsorption decrease the severity of MODS (multiple organ disfunction syndrome)?

The study will include participants aged 18 to 80 years with a verified diagnosis of septic shock according to SEPSIS 3 criteria, diagnosed within 12 hours, and a SOFA (sequential organ failure assessment) score of 9 or more.

In addition to Standard of Care (SOC), blood purification, including hemoadsorption, will be used. The minimum waiting time after diagnosis of septic shock and initiation of basic therapy before inclusion of the patient in the study therapy is 4 hours.

The choice of procedure will be based on the EAA (Endotoxin Activity Assay) result:

* for an EAA level of 0.6-0.9, selective lipopolysaccharide (LPS) adsorption with duration from 2 to 10 hours; * for an EAA level less than 0.6, inflammatory mediator adsorption with duration from 6 to 12 hours.

The choice of a specific adsorbers within the LPS and inflammatory mediator adsorption group will be based on randomization.

The use of LPS adsorption is planned based on randomization: Toramyxin R-20 or Efferon LPS. The use of inflammatory mediator adsorption is planned based on randomization: Jafron (HA 330) or CytoSorb.

The 4 groups in the trial

  • Inflammatory mediatiors adsorption with CytoSorbTreatment being tested

    Inflammatory mediatiors adsorption with EAA \<0,6 with CytoSorb

    Treatment: CytoSorb

  • Inflammatory mediatiors adsorption with Jafron HA 330Existing treatment, for comparison

    Inflammatory mediatiors adsorption with EAA \<0,6 with Jafron HA 330

    Treatment: Jafron HA 330

  • Endotoxin haemoadsorption with Toramyxin PMX 20RTreatment being tested

    Endotoxin haemoadsorption with EAA \[0.6-0.9\] with Toramyxin PMX 20R

    Treatment: Toramyxin PMX 20R

  • Endotoxin haemoadsorption with Efferon LPSExisting treatment, for comparison

    Endotoxin haemoadsorption with EAA \[0.6-0.9\] with Efferon LPS

    Treatment: Efferon LPS

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation. A Pilot Multicenter Randomized Controlled Trial
Criteria questions
Built from NCT07661303, who can take part
Record updated
2 July 2026